TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04745299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lenzumestrocel
Description: Single cycle administration group : injections twice in a 26-day interval Multiple administration group : injections twice in a 26-day interval followed by repeated three times injections every three months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lenzumestrocel
Description: Single cycle administration group : injections twice in a 26-day interval Multiple administration group : injections twice in a 26-day interval followed by repeated three times injections every three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: concomitant administration of Riluzole to all groups, except subjects to whom Riluzole administration is deemed impossible owing to adverse events as determined by medical experts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: concomitant administration of Riluzole to all groups, except subjects to whom Riluzole administration is deemed impossible owing to adverse events as determined by medical experts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: concomitant administration of Riluzole to all groups, except subjects to whom Riluzole administration is deemed impossible owing to adverse events as determined by medical experts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Single cycle administration group: Placebo comparator is injected three times every three months after injection of Lenzumestrocel twice in a 26-day interval.~Control group: Placebo comparator is injected twice in a 26-day interval followed by repeated three times injcections every three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Single cycle administration group: Placebo comparator is injected three times every three months after injection of Lenzumestrocel twice in a 26-day interval.~Control group: Placebo comparator is injected twice in a 26-day interval followed by repeated three times injcections every three months
Study: NCT06096519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information, motivation, behavioral skills treatment arm
Description: Our intervention will be an updated version of (Guy2Guy) G2G, a 2014 text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old gay, bisexual, and queer (GBQ) adolescent males. The treatment arm of G2G was guided by the Information-Motivation-Behavioral Skills (IMB) model and proved to be efficacious at increasing HIV testing in 13-18 year old GBQ adolescent males. In this updated version we will continue to utilize the IMB model, but modernize the content to include updated HIV prevention information (e.g., novel methods of HIV testing, PrEP, PEP) and tailor the text-message content to meet the needs of adolescent sexual minority men and transgender and gender diverse adolescents.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information only control arm
Description: This information only control arm will consist of content and text messages focused on health behavior information, including mood, sexual health, substance use, and other health behaviors. It will be identical in length to the intervention arm.
Study: NCT06635148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-81201887
Description: No study intervention will be administered as part of this LTE study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-81201887
Description: No study intervention will be administered as part of this LTE study.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: No study intervention will be administered as part of this LTE study.
Study: NCT05891548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS-AX
Description: CLS-AX will be administered by suprachoroidal injection into the study eye on Day 1 and then every 12 to 24 weeks as determined by protocol-defined disease activity criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept will be administered by intravitreal injection into the study eye once every 8 weeks (Q8W).
Study: NCT04825275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole Pill
Description: 300 mg (three 100 mg tablets) orally
Study: NCT06220604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-77242113 Matching Placebo
Description: JNJ-77242113 matching placebo will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-77242113 Matching Placebo
Description: JNJ-77242113 matching placebo will be administered orally.
Study: NCT05016349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 200mg capsules daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 200mg capsules daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 200mg capsules daily for 28 days
Study: NCT06220604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deucravacitinib
Description: Deucravacitinib will be administered orally.
Study: NCT05016349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 200mg capsules daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 200mg capsules daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Liquid taken orally for daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Liquid taken orally for daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Liquid taken orally for daily for 28 days
Study: NCT06220604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib Matching Placebo
Description: Deucravacitinib matching placebo will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib Matching Placebo
Description: Deucravacitinib matching placebo will be administered orally.
Study: NCT04667663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab (1,800mg) will be administered by a subcutaneous injection once every week for 2 cycles (Cycles 1-2), then once every 2 weeks for 4 cycles (Cycles 3-6), and following this (Cycle 7 onwards), patients will receive daratumumab once every four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered PO at 50mg daily for all cohorts in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered PO on days 1-21 of each 28 day cycle. The dose will be specified by the dose level to which the patient has been enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered PO at 40mg on days 1, 8, 15 and 22 of each 28 day cycle.
Study: NCT06122285

Intervention type: DRUG
Intervention: Bulevirtide
Description: dose of 2 mg/day subcutaneously
Study: NCT05904236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with ICVB-1042 administered intravenously
Description: Part A Dose Escalation to assess safety and tolerability of ascending dose levels, define the maximum tolerated dose (MTD), and expansion dose(s) Part B Dose Expansion to further assess safety and tolerability of 1 or more dose levels
Study: NCT04585438

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac Potassium
Description: The drug will be used as a transparent disc applied to the mucosa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium
Description: The drug will be used as a transparent disc applied to the mucosa
Study: NCT05856214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-Based Violence Prevention education(CBVPE)
Description: Couples in the intervention group will receive training on violence against women including intimate partner violence, types, and consequences of intimate partner violence during pregnancy, managing triggers of intimate partner violence, healthy relationships, the role of male partners during pregnancy, and couples communication and problem-solving skills. Training will be provided every fourth week by trained health extension workers for consecutive six months.
Study: NCT05535387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamilyNet smart speaker/mobile application
Description: In a 4- to 6-week period, families will use a prototype of the FamilyNet integrated and coordinated smart speaker/mobile application designed to provide families with in-situ experiential support for building positive behavior plans. The prototype FamilyNet program will guide families in creating and implementing positive behavior plans to foster positive child behavior, consistent parenting, and promote a positive parent-child relationship.
Study: NCT06386432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone App-delivered Smoking Cessation Intervention
Description: Receive access to EQQUAL-NM (Program A) intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone App-delivered Smoking Cessation Intervention
Description: Receive access to EQQUAL-NM (Program B) intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive text message reminders, motivational messages and prompts via SMS text messages (Program A)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion and Education
Description: Receive text message reminders, motivational messages and prompts via SMS text messages (Program B)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Complete at-home saliva sample collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Complete at-home saliva sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05073042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning exercise goal
Description: Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes between 5 AM and 10 AM each day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening exercise goal
Description: Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes between 5 PM and 10 PM each day.
Study: NCT05016349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Liquid taken orally for daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Liquid taken orally for daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Liquid taken orally for daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Liquid taken orally for daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9 cis retinoic acid
Description: 9 cis retinoic acid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
Study: NCT05073042

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time of choice exercise goal
Description: Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes at a time of their choice each day. This time can change day-to-day.
Study: NCT06684808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitness
Description: The Fitness group engaged in active breaks aimed at improving cardiovascular efficiency. These breaks were designed to provide moderate to vigorous physical activity, incorporating both strength and aerobic exercises such as squats, jumping jacks, lunges, and running in place. Children were instructed to imitate the teacher's movements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative
Description: The Creative group participated in active breaks that combined cognitive-creative and physical demands, incorporating activities like improvisations, dramatizations of events or short stories, simulation, and imitation games. These activities aimed to stimulate the creative process and enhance emotional expression within environmental constraints. Constraints, set by the teacher-such as specific rules, partner positioning, or speed of execution-limited movement options, encouraging students to explore new solutions to complete each task.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined
Description: The Combined group took active breaks by combining the Fitness protocol in the first break and the Creative protocol in the second.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Regular physical activity at school during the weeks.
Study: NCT06685614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic bracket bonding
Description: compare the effectiveness of different bonding methods including traditional direct bonding, traditional indirect bonding, indirect bonding using 3D-printed transfer tray, and indirect bonding using vacuum-formed transfer tray made with 3D-printed models

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic bracket bonding
Description: compare the effectiveness of different bonding methods including traditional direct bonding, traditional indirect bonding, indirect bonding using 3D-printed transfer tray, and indirect bonding using vacuum-formed transfer tray made with 3D-printed models

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic bracket bonding
Description: compare the effectiveness of different bonding methods including traditional direct bonding, traditional indirect bonding, indirect bonding using 3D-printed transfer tray, and indirect bonding using vacuum-formed transfer tray made with 3D-printed models

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic bracket bonding
Description: compare the effectiveness of different bonding methods including traditional direct bonding, traditional indirect bonding, indirect bonding using 3D-printed transfer tray, and indirect bonding using vacuum-formed transfer tray made with 3D-printed models
Study: NCT05016349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9 cis retinoic acid
Description: 9 cis retinoic acid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard therapy
Description: Patients will receive the approved standard therapy tamoxifen
Study: NCT06528665

Intervention type: DRUG
Intervention: ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults
Description: ZEPOSIA®~* Titration is required for treatment initiation.~* The recommended maintenance dosage is 0.92 mg orally once daily.~* If a dose is missed within the first 2 weeks of treatment, reinitiate with the titration regimen. If a dose is missed after the first 2 weeks of treatment, continue treatment as planned.
Study: NCT06682780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-2417
Description: Q2W/Q3W,Intravenous Drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-2417
Description: Q2W/Q3W,Intravenous Drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-2417
Description: Q2W/Q3W,Intravenous Drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Q3W,Intravenous Drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Q3W,Intravenous Drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab/Tirelizumab
Description: Q3W,Intravenous Drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab/Tirelizumab
Description: Q3W,Intravenous Drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Q3W,Intravenous Drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Q3W,Intravenous Drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: QD,Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: QD,Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: QD,Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: QD,Oral Administration
Study: NCT06685744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation_TRsA
Description: Frequency: 5 weeks (4 sessions/week) of Telerehabilitation intervention provided according to a mixed model (3 asynchronous sessions + 1 synchronous session/week); Intensity: customized according to the patient's functional abilities (system's feedback); Time: 50 minutes/session; Type: exercises aimed at improving functional mobility and physical capacity according to a Task-oriented approach.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational treatment
Description: Home rehabilitation indications according to a conventional approach, customized according to the disease.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation_TRcA
Description: Frequency: 5 weeks (4 sessions/week) of Telerehabilitation intervention provided according to a mixed model (3 asynchronous sessions + 1 synchronous session/week); Intensity: customized according to the patient's functional abilities (system's feedback); Time: 50 minutes/session; Type: a combination of exercises aimed at improving functional mobility and physical capacity according to a Task-oriented approach together with exercises aimed at recovering muscle strength (resistance) and improving endurance (endurance) using an Impairment-oriented approach.
Study: NCT06668441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery plus low-dose rhTNK-tPA group
Description: The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.001mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery plus medium dose rhTNK-tPA group
Description: The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.003mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery plus high dose rhTNK-tPA group
Description: The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.009mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.
Study: NCT06627309

Intervention type: DRUG
Intervention: Dara IV
Description: The treament follow the clinical routine practice, as daratumumab 16mg/kg iv qw OR dara SC 1800mg initially. The treatment schedule involve weekly administrations during cycles 1 to 2, following by biweekly administrations during cycles 3 to 6. Subsequently, monthly administrations are given as monotherapy.

Intervention type: DRUG
Intervention: Bortezomib (drug)
Description: Bortezomib is administered subcutaneously. The dosage range from 0.7 to 1.3 mg/m2 on days 1, 8, 15, and 22 of each cycle, for a maximum of 6 cycles

Intervention type: DRUG
Intervention: Dexamethasone
Description: Dexamethasone is administered intravenously at a dose of 40 mg weekly for each cycle, for a maximum of 6 cycles. For patients over 70 years of age or with severe edema, heart failure, or uncontrolled diabetes mellitus, dexamethasone can be administered at a dose of 10-20 mg per week.
Study: NCT05535257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sequential Compression Device
Description: Calf size lower extremity sequential compression device sleeve will be placed on the weak upper extremity blow the cubital fossa and may include the hand if necessary. The device will inflate and deflate.